Emergent BioSolutions (EBS) Operating Margin (2011 - 2026)

Emergent BioSolutions' Operating Margin history runs 16 years deep, the most recent figure standing at 6.73% for Q1 2026.

• On a quarterly basis, Operating Margin fell 1573.0% year-over-year to 6.73% in Q1 2026; TTM through Mar 2026 was 8.97%, a 2193.0% increase from a year earlier, with the FY2025 full-year figure at 13.47%, up 2389.0% from the prior year.
• Operating Margin grew to 6.73% in Q1 2026 per EBS's latest filing, from 18.76% in the prior quarter.
• Across five years, Operating Margin topped out at 33.1% in Q3 2025 and bottomed at 407.0% in Q2 2024.
• The 5-year median for Operating Margin is 15.84% (2023), against an average of 39.92%.
• Across the five-year window, Operating Margin tumbled 32032 bps in 2024 and surged 40814 bps in 2025, its largest moves.
• Year by year, Operating Margin stood at 16.75% in 2022, then climbed by 5 bps to 15.84% in 2023, then surged by 69 bps to 4.88% in 2024, then slumped by 285 bps to 18.76% in 2025, then surged by 136 bps to 6.73% in 2026.
• Per Business Quant, the three latest EBS Operating Margin figures stand at 6.73% (Q1 2026), 18.76% (Q4 2025), and 33.1% (Q3 2025).